AR036036A1 - Compuesto heterociclico, composicion farmaceutica que lo contiene y su uso para la preparacion de la misma - Google Patents
Compuesto heterociclico, composicion farmaceutica que lo contiene y su uso para la preparacion de la mismaInfo
- Publication number
- AR036036A1 AR036036A1 ARP020102002A ARP020102002A AR036036A1 AR 036036 A1 AR036036 A1 AR 036036A1 AR P020102002 A ARP020102002 A AR P020102002A AR P020102002 A ARP020102002 A AR P020102002A AR 036036 A1 AR036036 A1 AR 036036A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- agent
- hydrogen atom
- aryl
- atom
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000003118 aryl group Chemical group 0.000 abstract 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 239000003524 antilipemic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical group FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto heterocíclico que tiene la fórmula (1) donde R1 es un átomo de hidrógeno o alquilo C1-6; R2 es un átomo de hidrógeno, -CO-R3, donde R3 es alquilo C2-6 opcionalmente sustituido por halógeno, -CO-C(R4)=C(R4)-R5, donde R4 es opcionalmente el mismo que el otro R4 y es un átomo de hidrógeno o alquilo C1-4 y R5 es alquilo C1-8, alquenilo C2-8, arilo o un heterociclo aromático, -CO-C:::C-R6, donde R6 es alquilo C1-8, fórmula (2) donde m es un número entero de 2 a 7, arilo, arilalquilo C1-3 opcionalmente sustituido, alquilo C1-6 opcionalmente sustituido por halógeno, alquenilo C2-6, cicloalquilo C3-8 o cicloalquil C3-8-alquilo C1-3; Y es fórmula (3) donde R7 es un átomo de hidrógeno o alquilo C1-4; R8 es alquilo C5-8, cicloalquilo C4-8, alquiltio C1-4-alquilo C1-6, R10-C(R9)=C(R9)-, donde R9 es opcionalmente el mismo que el otro R9 y es un átomo de hidrógeno o alquilo C1-4 y R10 es alquilo C1-6 opcionalmente sustituido por halógeno, alquenilo C2-8, arilo, un heterociclo aromático, cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-3, alcoxi C1-4-alquilo C1-6, alquiltio C1-4-alquilo C1-6 o alquilo C1-6 sustituido por (R9)2N-, donde R9 es opcionalmente el mismo que el otro R9 y es un átomo de hidrógeno o alquilo C1-4, R12-CO-N(R11)-, donde R11 es un átomo de hidrógeno o alquilo C1-4 y R12 es alquilo C1-6 o arilo, R13-Z-, donde R13 es alquilo C1-8 o arilo y Z es un átomo de oxígeno o un átomo de azufre; o fórmula (4) donde k es un número entero de 2 a 7 y X es un átomo de oxígeno o un átomo de azufre, o R15-C(R14)=N-O-, donde R14 es un átomo de hidrógeno o alquilo C1-4 y R15 es arilo o un heterociclo aromático; Y-(CH2)n-O- está enlazado a la posición 6 o 7 de un esqueleto de tetrahidroisoquinolina; y n es un número entero de 1 a 4, o una sal farmacéuticamente aceptable del mismo. Composición farmacéutica que lo comprende y su uso para prepararla, siendo útil como agente hipoglucémico, un agente hipolipidémico, un mejorador de la resistencia a la insulina, un agente terapéutico de la diabetes, un agente terapéutico de complicaciones diabéticas, un mejorador de la tolerancia a la glucosa, un agente antiarterioesclerosis, un agente antiobesidad, un agente antiinflamatorio, un agente para la profilaxis o tratamiento de enfermedades mediadas por PPAR o un agente para la profilaxis o el tratamiento del síndrome X.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001161489 | 2001-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR036036A1 true AR036036A1 (es) | 2004-08-04 |
Family
ID=19004756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102002A AR036036A1 (es) | 2001-05-29 | 2002-05-29 | Compuesto heterociclico, composicion farmaceutica que lo contiene y su uso para la preparacion de la misma |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7557123B2 (es) |
| EP (1) | EP1403253A4 (es) |
| JP (1) | JP4279136B2 (es) |
| KR (2) | KR100898358B1 (es) |
| CN (1) | CN1242994C (es) |
| AR (1) | AR036036A1 (es) |
| AU (1) | AU2002308889B2 (es) |
| BR (1) | BR0209711A (es) |
| CA (1) | CA2448634A1 (es) |
| CO (1) | CO5540342A2 (es) |
| CZ (1) | CZ20033450A3 (es) |
| HU (1) | HUP0401862A3 (es) |
| IL (1) | IL159085A0 (es) |
| MX (1) | MXPA03010811A (es) |
| NO (1) | NO326688B1 (es) |
| NZ (1) | NZ530358A (es) |
| PL (1) | PL367639A1 (es) |
| RU (1) | RU2299197C2 (es) |
| TW (1) | TWI297008B (es) |
| WO (1) | WO2002096880A1 (es) |
| YU (1) | YU94003A (es) |
| ZA (1) | ZA200309757B (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2287529C2 (ru) | 2001-05-29 | 2006-11-20 | Киото Фармасьютикал Индастриз, Лтд. | Новые гетероциклические производные и их медицинское использование |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| WO2004106542A1 (ja) * | 2003-05-29 | 2004-12-09 | Sankyo Company, Limited | インスリン抵抗性改善剤及びそのスクリーニング方法 |
| TWI359810B (en) | 2004-11-04 | 2012-03-11 | Mitsubishi Tanabe Pharma Corp | Carboxylic acid derivative containing thiazole rin |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| WO2007058504A1 (en) * | 2005-11-21 | 2007-05-24 | Lg Life Sciences, Ltd. | Novel compounds as agonist for ppar gamma and ppar alpha, method for preparation of the same, and pharmaceutical composition containing the same |
| RU2411936C2 (ru) * | 2009-01-11 | 2011-02-20 | Институт физиологии Коми научного центра Уральского отделения Российской академии наук. Государственное учреждение | Применение 2-морфолино-5-фенил-6н-1,3,4-тиадизин, гидробромида в качестве средства, обладающего гиполипидемическим и гипергликемическим эффектом |
| WO2012033195A1 (ja) * | 2010-09-10 | 2012-03-15 | 京都薬品工業株式会社 | 複素環化合物 |
| CN102807526B (zh) * | 2011-06-21 | 2015-12-02 | 寿光富康制药有限公司 | 组蛋白去乙酰化酶抑制剂ZYJ-D08a及其差向异构体的制备方法与应用 |
| WO2020013116A1 (ja) * | 2018-07-10 | 2020-01-16 | 京都薬品工業株式会社 | Ｐｔｐ－１ｂ阻害剤およびその用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6051189A (ja) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | チアゾリジン誘導体およびその製造法 |
| AR240698A1 (es) * | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
| DE3856378T2 (de) * | 1987-09-04 | 2000-05-11 | Beecham Group P.L.C., Brentford | Substituierte Thiazolidindionderivate |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| WO1998000403A1 (en) * | 1996-07-01 | 1998-01-08 | Eli Lilly And Company | Hypoglycemic and hypolipidemic compounds |
| CA2259487A1 (en) | 1996-07-01 | 1998-01-08 | Margaret Mary Faul | Hypoglycemic and hypolipidemic compounds |
| GB9817118D0 (en) * | 1998-08-07 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| CA2393265A1 (en) * | 1999-12-03 | 2001-06-07 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic compounds and salts thereof and medicinal use of the same |
| US20020037897A1 (en) | 2000-08-07 | 2002-03-28 | 3-Dimensional Pharmaceuticals, Inc. | Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists |
| RU2287529C2 (ru) | 2001-05-29 | 2006-11-20 | Киото Фармасьютикал Индастриз, Лтд. | Новые гетероциклические производные и их медицинское использование |
-
2002
- 2002-05-27 MX MXPA03010811A patent/MXPA03010811A/es active IP Right Grant
- 2002-05-27 EP EP02774070A patent/EP1403253A4/en not_active Withdrawn
- 2002-05-27 HU HU0401862A patent/HUP0401862A3/hu unknown
- 2002-05-27 KR KR1020087023698A patent/KR100898358B1/ko not_active Expired - Fee Related
- 2002-05-27 CZ CZ20033450A patent/CZ20033450A3/cs unknown
- 2002-05-27 YU YU94003A patent/YU94003A/sh unknown
- 2002-05-27 WO PCT/JP2002/005097 patent/WO2002096880A1/ja not_active Ceased
- 2002-05-27 CA CA002448634A patent/CA2448634A1/en not_active Abandoned
- 2002-05-27 PL PL02367639A patent/PL367639A1/xx unknown
- 2002-05-27 RU RU2003137574/04A patent/RU2299197C2/ru not_active IP Right Cessation
- 2002-05-27 BR BR0209711-7A patent/BR0209711A/pt not_active IP Right Cessation
- 2002-05-27 IL IL15908502A patent/IL159085A0/xx unknown
- 2002-05-27 AU AU2002308889A patent/AU2002308889B2/en not_active Ceased
- 2002-05-27 CN CNB028109643A patent/CN1242994C/zh not_active Expired - Fee Related
- 2002-05-27 US US10/478,862 patent/US7557123B2/en not_active Expired - Fee Related
- 2002-05-27 JP JP2003500060A patent/JP4279136B2/ja not_active Expired - Fee Related
- 2002-05-27 ZA ZA200309757A patent/ZA200309757B/en unknown
- 2002-05-27 KR KR10-2003-7015611A patent/KR20040030647A/ko not_active Withdrawn
- 2002-05-27 NZ NZ530358A patent/NZ530358A/en unknown
- 2002-05-28 TW TW091111315A patent/TWI297008B/zh active
- 2002-05-29 AR ARP020102002A patent/AR036036A1/es unknown
-
2003
- 2003-11-28 NO NO20035331A patent/NO326688B1/no not_active IP Right Cessation
- 2003-12-29 CO CO03112806A patent/CO5540342A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2002096880A1 (ja) | 2004-09-09 |
| KR20040030647A (ko) | 2004-04-09 |
| CA2448634A1 (en) | 2002-12-05 |
| KR100898358B1 (ko) | 2009-05-20 |
| ZA200309757B (en) | 2004-12-22 |
| EP1403253A1 (en) | 2004-03-31 |
| RU2299197C2 (ru) | 2007-05-20 |
| CN1527819A (zh) | 2004-09-08 |
| HUP0401862A3 (en) | 2009-03-30 |
| PL367639A1 (en) | 2005-03-07 |
| AU2002308889B2 (en) | 2007-09-06 |
| IL159085A0 (en) | 2004-05-12 |
| TWI297008B (en) | 2008-05-21 |
| NZ530358A (en) | 2005-04-29 |
| NO326688B1 (no) | 2009-01-26 |
| US20040220215A1 (en) | 2004-11-04 |
| HUP0401862A2 (hu) | 2004-12-28 |
| WO2002096880A1 (en) | 2002-12-05 |
| BR0209711A (pt) | 2004-11-03 |
| CZ20033450A3 (cs) | 2004-05-12 |
| KR20080093076A (ko) | 2008-10-17 |
| RU2003137574A (ru) | 2005-05-20 |
| EP1403253A4 (en) | 2005-03-30 |
| CO5540342A2 (es) | 2005-07-29 |
| US7557123B2 (en) | 2009-07-07 |
| JP4279136B2 (ja) | 2009-06-17 |
| HK1069385A1 (en) | 2005-05-20 |
| MXPA03010811A (es) | 2004-02-27 |
| NO20035331D0 (no) | 2003-11-28 |
| CN1242994C (zh) | 2006-02-22 |
| YU94003A (sh) | 2006-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9910371A (pt) | Composto, composição farmacêutica, agente para controlar os receptores relacionados com a retinóide, processos de prevenção e terapia da diabetes mellitus, de prevenção e terapia da hiperlipemia, para acentuar uma sensibilidade à insulina, para melhorar uma resistência à insulina, de prevenção e terapia da tolerância à glicose prejudicada, de prevenção e terapia de uma doença inflamatória, de prevenção de uma esclerose arterial, e, uso do composto | |
| DE60218048D1 (de) | Thiophenverbindungen als arzneimittel | |
| BRPI0513752A (pt) | derivado de ciclohexano, pró-droga do mesmo e sal do mesmo e agente terapêutico contendo o mesmo para diabetes | |
| RU2000131183A (ru) | Производные оксииминоалкановой кислоты | |
| AR036036A1 (es) | Compuesto heterociclico, composicion farmaceutica que lo contiene y su uso para la preparacion de la misma | |
| DK1045830T3 (da) | Alfa-aminoamidderivater, der er anvendelige som analgetiske midler | |
| BR0211665A (pt) | Composto, composição farmacêutica, método para a redução de glicose, método para a prevenção ou para tratamento de doenças, medicamento para a redução de glicose, medicamento para a prevenção ou para o tratamento de doenças, uso do composto, da composição farmacêutica e do medicamento e processo para a preparação do composto | |
| WO2004073611A3 (en) | Compounds for the treatment of metabolic disorders | |
| AR036037A1 (es) | Compuesto heterociclico, composicion farmaceutica que lo comprende y su uso para la preparacion de esta ultima | |
| ATE487474T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ATE526018T1 (de) | Verbindungen zur behandlung von stoffwechselstörungen | |
| ES2051834T3 (es) | El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad. | |
| ATE420853T1 (de) | 5-amidino-2-hydroxybenzolsulfonamidderivate, pharmazeutischen zusammensetzungen, die diese verbindungen enthalten, und zwischenprodukte zu deren herstellung | |
| AR044869A1 (es) | Compuesto de dicetopiperazina, composicion farmaceutica que lo comprende, su uso para fabricar un medicamento y procedimiento para su preparacion | |
| ES2059348T3 (es) | Composicion farmaceutica para el tratamiento de cataratas. | |
| DK1179342T3 (da) | Medicinske sammensætninger til öjeblikkelig frigivelse ved oral anvendelse | |
| SE0101978D0 (sv) | New compounds | |
| DE60013560D1 (de) | Malto-oligosaccharid-derivate und ihre anwendungen | |
| RU2008101661A (ru) | Замещенное циклическое соединение, способ его получения и его лекарственное применение | |
| EA200400192A1 (ru) | Фармацевтическая композиция для лечения заболеваний, характеризующихся снижением и/или нарушением когнитивных функций | |
| RU2005124286A (ru) | Производное олигосахаридов | |
| DE602004018634D1 (de) | Carbonsäureverbindung und arzneimittel welches diese enthält | |
| KR940002268A (ko) | 21-클로로-프레그난 유도체 | |
| MXPA98001514A (es) | Opiatos hiperalgesico activos perifericamente | |
| SE9904416D0 (sv) | Crystalline form |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |